New drug aims to shield patients from Chemo's harsh side effects
NCT ID NCT07490236
Summary
This study is testing whether a drug called trilaciclib can protect patients' bone marrow from damage during chemotherapy for solid tumors. Researchers will enroll 100 patients to see if the drug reduces severe blood cell drops, which are common and dangerous side effects of cancer treatment. They will also try to build a model to predict which patients are most likely to benefit from this protective treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRILACICLIB are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Fourth Hospital of Hebei Medical University
RECRUITINGShijiazhuang, Hebei, 050300, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.